

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A synthetic monomeric, cyclic B-chain peptide ~~analogue of a B-chain~~ of a relaxin superfamily member protein which binds to a biological target of the relaxin superfamily protein, and modulates an activity of the biological target, wherein the relaxin superfamily protein is selected from insulin, IGF-I, IGF-II, relaxin 1, relaxin 2, relaxin 3, INSL3, INSL4, INSL5 and INSL6, which relaxin superfamily protein corresponds to SEQ ID NO: 1, 2, 3, 7, 8, 9, 10, respectively, the biological target being selected from insulin receptors, IGFR-I, IGFR-II, LGR7 and LGR8 and wherein the ~~analogue cyclic peptide has an intrapeptide cyclization modification is produced by modification of a turn or loop moiety to produce a cross-link between a first amino acid within a range of amino acid positions 2 and 8 and a second amino acid within a range of positions 21 and 26 of each of said peptide sequences, the B-chain of the relaxin superfamily protein, the modification involving selection of at least a first and a second amino acid residue with an alpha-helix or beta-strand carbon separation distance of less than six angstroms and cross-linking the first and second amino acids~~, wherein the cross-link conformationally constrains the analogue peptide, and wherein said intrapeptide cyclization is via the formation of a covalent bond between the side chains of said first and second amino acids or a disulfide bond between two cysteine residues, wherein said two cysteine residues are substituted for said first and said second amino acids, or a thioether bond between a substituted cysteine residue at said first or said second amino acid and a halogenated amino acid residue at the other position, either directly or via a spacer group.

2. (canceled)

3. (currently amended) The peptide analogue according to claim 1, wherein the peptide analogue is an INSL3 B-chain analogue modified from a sequence set forth in SEQ ID NO:7.

4. (withdrawn – currently amended) The peptide analogue according to claim 3, wherein the INSL3 peptide analogue is constrained by a cross-link between a first amino acid within a range of positions 2 and 8 and a second amino acid within a range of positions 21 and 26 of the sequence set forth in SEQ ID NO:7.

5.-6. (canceled)

7. (withdrawn - currently amended) The peptide analogue according to claim 1, which is a relaxin peptide analogue modified from a relaxin-1, relaxin-2, or relaxin-3 B-chain sequence set forth in SEQ ID NOs: 1, 2 and 3, respectively.

8. (withdrawn - currently amended) The peptide analogue according to claim 7, wherein the relaxin peptide analogue is constrained by a cross-link between a first amino acid within a range of positions 2 and 8 and a second amino acid within a range of positions 21 and 26 of the sequence set forth in SEQ ID NO:2.

9. (canceled)

10. (withdrawn – currently amended) The peptide analogue according to claim 1, wherein the first and/or second amino acids are substituted with alternative amino acids suitable for cross-linking.

11. (withdrawn - currently amended) The peptide analogue according to claim 10 wherein at least one of the alternative amino acids is a cysteine residue.

12. (withdrawn - currently amended) The peptide analogue according to claim 11 wherein both of the alternative amino acid residues are cysteine residues.

13. (withdrawn - currently amended) The peptide analogue according to claim 12 wherein the peptide analogue is cross-linked by oxidizing the cysteine residues to form a disulfide bond between the cysteine residues.

14. (withdrawn - currently amended) ~~[[An]]~~ A peptide analogue according to claim 1, wherein one or more amino acids within the ~~INSL3~~ INSL or relaxin peptide analogue sequence, other than the cross-linked first and second amino acids, is substituted to modify one or more biological activities of the peptide analogue.

15. (withdrawn - currently amended) The peptide analogue according to claim 1 wherein the biological target of the peptide analogue is LGR7 and/or LGR8.

16. (withdrawn - currently amended) The peptide analogue according to claim 15, wherein activity of the biological target is initiated, up-regulated, down-regulated or otherwise blocked.

17. (withdrawn - currently amended) The peptide analogue of claim 1, wherein the peptide analogue is conjugated to an A-chain of a relaxin superfamily protein.

18. (withdrawn - currently amended) The peptide analogue according to claim 17, wherein the A-chain of the relaxin superfamily protein is derived from the relaxin superfamily protein from which the B chain peptide analogue is derived.

19. (withdrawn- currently amended) The peptide analogue according to claim 1, wherein the peptide analogue is conjugated to a reporter group.

20. (withdrawn - currently amended) The peptide analogue according to ~~[[the]]~~ claim 19, wherein the reporter group is a radiolabel.

21. (withdrawn - currently amended) The peptide analogue according to claim 19, wherein the reporter group is a fluorescent label.

22. (withdrawn - currently amended) The peptide analogue according to claim 19, wherein the reporter group is an enzyme.

23. (withdrawn - currently amended) The peptide analogue according to claim 19, wherein the reporter group is a carrier.

24.-31. (canceled)

32. (currently amended) A pharmaceutical composition including one or more of the peptides analogues as claimed in claim 1, or pharmaceutically acceptable salts thereof.

33. (original) The pharmaceutical compositions according to claim 32, further comprising at least one pharmaceutically acceptable carrier or diluent.

34.-49 (canceled)

50. (withdrawn - currently amended) The peptide analogue according to claim 1, ~~wherein the analogue is an INSL3 analogue~~ with the following sequence and structure:

TPCMREKLSGHHFVRALVRVSGGPCWS₁

51. (withdrawn - currently amended) The peptide analogue according to claim 1, ~~wherein the analogue is an INSL3 analogue~~ with the following sequence and structure:

TPCMREKLSGRHFVRALVRVSGGPCWS₂

52. (withdrawn - currently amended) The peptide analogue according to claim 1, ~~wherein the analogue is a relaxin analogue~~ with the following sequence and structure:

SCMEEVIKLSGRELVRAQIAISGCS₂